and Hughes R. A.C., 1995., Campylobacter jejuniinfection and Guillain-Barre syndrome, The New England Journal of Medicine, vol.333, no. 21, 1374-1379Rose N.R. and Mackay, I.R. 2000. Molecular mimicry: a critical look at exemplaryinstances in human diseases. Cell. Mol. Life Sci. 57, 542-551Sheikh K. A., I. Nachamkin, T. W. Ho, H. J. Willison, J. Veitch, H. Ung, M. Nicholson, C.Y. Li, H. S. Wu, B. O. Shen, D. R. Cornblath, A. K. Asbury, G. M. McKhann, and J. W.Griffin. 1998. Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome:molecular mimicry and host susceptibility. Neurology 51:371-378.Van Doorn P.A 2008. Clinical features, pathogenesis, and treatment of Guillain-Barresyndrome, The Lancet Neurology, vol. 7, no. 10, 939-950Wirguin I., Briani C., Suturkova-Milosevic L., Fisher T., Della-Latta P., Chalif P., andLatov N., 1997. Induction of anti-GM1 ganglioside antibodies by Campylobacter jejunilipopolysaccharides. J. Neuroimmunol. 78:138-142.Yuki N., Yamada M., M. Koga, 2001. Animal model of axonal Guillain-Barre syndromeinduced by sensitization with GM1 ganglioside, Annals of Neurology, vol. 49, no. 6,pp. 712-720Yuki N., K. Susuki, M. Koga, Y. Nishimoto, M. Odaka, K. Hirata, K. Taguchi, T. Miyatake,K. Furukawa, T. Kobata, and M. Yamada. 2004. Carbohydrate mimicry between humanganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barresyndrome. Proc. Natl. Acad. Sci. USA 101:11404-11409.SOzDAVAnjE NA ANTI-GANGlIOzIDNIANTITElA VO zhIVOTINSKI MODElNA guIllaIn-barre SINDROMOTGrozdanova Aleksandra1, Potseva-Panovska Ana1,Brezovska Katerina1, Trajkovska-Dokikj Elena2,Apostolski Slobodan3, Shuturkova Ljubitsa11Institut za Farmatsevtska khemija, Farmatsevtski fakultet, Un. "Sv.Kiril i Metodij", Skopje, Makedonija2Institut za Mirobilogija i parazitologija, Meditsinski fakultet,Un. "Sv. Kiril i Metodij", Skopje, Makedonija3Ordinatsija za nevrologija "Dr. Apostolski", Belgrad, SrbijaVOVEDEksperimentalnite dokazi dobieni od khumani i zhivotinskiistituvanja ja potvrduvaat khipotezata deka jaglekhidratnata mimi-krija pomegju lipopolisakharidite (LPS) od odredeni Campylobacterjejuni (C. jejuni) serotipovi i khumanite nevronski gangliozidi mozheda rezultiraat so sozdavanje na antigangliozidni antitela koiigraat glavna uloga vo patogenezata na Guillain-Barre sindromot(GBS).Ponovite podatotsi pokazhuvaat deka edna tretina od patsientiteso GBS imaat potvrdena predkhodna infektsija so C. jejuni, i dekaspetsifichni serotipovi na C. jejuni se asotsirani so razvivanje naGBS. C. jejuni serotipot O:19 e najchesto asotsiran so GBS, a postojatpodatotsi za asotsiranost i so O:2, O:15, O:18, O:24, O:30, O:37 iO:53 serotipovite. Zhivotinskite modeli koi se koristat za da sereprodutsira GBS mozhe da se dobijat preku infektsija ili imuniza-tsija so infektiven agens ili prochisten antigen so tsel da sepottikne vkrsteno-reaktiven imun odgovor, klinichki simptomi ilida se ispituvaat drugi aspekti na predlozhenata molekularna mi-mikrija.TsElTselta na ovaa studija e da se ispita dali imunizatsijata na zajtsi soLPS od razlichni C. jejuni serotipovi izolirani od nekomplikuvanipatsienti so enteritis, kje dovede do sozdavanje na antigangli-ozidni i anti-LPS antitela. Beshe sleden i razvojot na patofi-zioloshkite karakteristiki vo imuniziranite zhivotni.MATERIJAlI I METODIBeli zajtsi od sojot New Zealand bea imunizirani so LPS od C. jejuniserotipovite 0:3, 0:19, 0:27, 0:37 izolirani od patsienti so ente-ritis i so C. jejuni LPS 0:19 (ATCC 700297) referentniot soj od pa-tsient so GBS. Vo strukturata na LPSs koristeni za imunizatsijabeshe potvrdeno prisustvoto na vkrsteno-reaktivni gangliozidslichni epitopi, preku studii so vrzuvanje so kolera toksin B sub-edinitsa i lektin od kikirika. Kaj serotipot 0:3 otsustvuva gan-liozid slichna struktura i ovoj serotip beshe koristen kako nega-tivna kontrola. Bea koristeni kompleten Freund adjuvans (CFA) ikejkhol-lifet khemotsijanid (KLH) kako adjuvansi.REzUlTATIImuniziranite zhivotni bea testirani sekoi 2 nedeli vo periodod 6 mesetsi za prisustvo na IgG i IgM anti-gangliozidni (GM1 iAG1) i anti-LPS antitela so upotreba na ELISA. Fetsesot na siteimunizirani zhivotni beshe negativen, upatuvajkji deka pokachuvanje-to na antitelata e indutsirano od imunizatsijata a ne od istovreme-na infektsijata so C. jejuni. Dopolnitelno, anti-gangliozidnite ianti- LPS antitela ne bea prisutni vo serumot na zhivotnite predimunizatsija. Kaj kontrolnata grupa na zhivotni imunizirana so adju-vanti ne se javi nitu anti-LPS nitu anti-ganglioziden odgovor. Ge-neralno kaj site zajtsi imunizirani so LPS dojde do sozdavanje naIgM i IgG anti-LPS antitela koi mozhea da se detektiraat nekolkunedeli pred anti-gangliozidniot odgovor. Zgolemeno nivo na IgMantitela kon LPS mozhe da se detektiraat 14 dena po prvata injek-tsija so LPS dodeka IgG odgovorot kon LPS beshe prisuten posle 28dena i prodolzhi da pokachuva vo tek na imunizatsioniot period.Zajtsite imunizirani so LPS O:19 GBS asotsiraniot serotip (ATCC700297) imaa najvisok IgM i IgG anti-GM1 antitela, i visok anti-GA1 IgG. Silen IgG i IgM GM1 antitelen odgovor se javi kaj zhi-votnite imunizirani so LPS O:19 izolatot od enteritis patsient, soblago pokachuvanje na IgG anti-GA1. Serotipovite 0:27 i 0:37 od en-teritis patsientite indutsiraat pokachuvanje na IgG anti-GA1 antite-la, no nisko nivo na anti-GM1 antitela beshe opredeleno.Imunizatsijata so LPS serotip O:3 koj ne sodrzhi gangliozidnastruktura, rezultirashe samo so silen anti-LPS odgovor, bez re-aktivnost kon gangliozidite.324PETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOMakedonski farmatsevtski bilten 57 (dodatok), 2011KLINIChKA FARMATsIJA oralni prezentatsiizAKlUChOTsIZhivotnite ne razvija bilo kakvi nevroloshki simptomi vo tek na 6mesetsi na sledenje, no beshe zabelezhano gubenje na tezhina, partsi-jalna slabost i otsustvo na reaktivnost kaj zhivotnite. Serumot odimuniziranite zhivotni so visok titar na GM1 i AG1 antitela rea-girashe so LPSs od C. jejuni izolirani od patsienti so enteritis,upatuvajkji deka jaglekhidratnata mimikrija megju gangliozidite i C.jejuni LPS indutsira sozdavanje na vkrsteno reaktivni avto antitelakoi najverojatno initsiraat razvivanje na GBS.lITERATURAAng C.W., De Klerk M. A., Endtz H. P., Jacobs B.C., Laman J. D., Van der Meche F.G.A.and Van Doorn P.A., 2001. Guillain-Barre syndrome and Miller-Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1bantibodies in rabbits. Infect. Immun. 69: 2462-2469Ang C.W., Jacobs B.C., Laman J.D., 2004. The Guillain-Barre syndrome: a true case ofmolecular mimicry. Trends Immunol. 25:61-66.Ariga T. and Yu R. K., 2005. Anti-glycolipid antibodies in Guillain-Barre syndrome andrelated diseases: review of clinical features and antibody specificities. J. Neurosci.Res. 80:1-17.Aspinall G.O., McDonald A.G., Raju T.S., Pang H., Moran A.P. and Penner J.L., 1993.Chemical structures of the core regions of Campylobacter jejuni serotypes O:1, O:4,O:23, and O:36 lipopolysaccharides. Eur. J. Biochem. 213:1017-1027.Grozdanova A., Poceva A., Brezovska K., Trajkovska-Dokic E., Apostolski S. andSuturkova Lj., 2011. Cross-reactive epitopes in Campylobacter jejuni strains isolatedfrom enteritis patients, Prilozi MASA, june 2011 (in press)Hughes R.A. 1999. Pathogenesis of Guillain-Barre' syndrome. J. Neuroimmunol. 100,74-97Hughes R.A. 2005. Multidisciplinary Consensus Group. Supportive care for patientswith Guillain-Barre syndrome. Arch., Neurol. 62: 1194-1198.Hughes R.A., Swan A. V., Raphal J., Annane D. and Van Doorn P.A. 2007.Immunotherapy for Guillain-Barree syndrome: a systematic review Brain, vol. 130,2245-2257Illa I., Ortiz N., Gallard E., Juarez C., Grau J.M. and Dalakas M.C. 1995. Acute axonalGuillain-Barresyndrome with IgG antibodies against motor axons following parenteralgangliosides. Ann Neurol; 38:218-24.Ilyas A.A., Willison H.J., Quarles R.H., Jungalwala F.B., Cornblath D.R., Trapp B.D.,Griffin D.E., Griffin J.W. and McKhann G.M. 1988. Serum antibodies to gangliosides inGuillain-Barre syndrome. Ann Neurol 23:440-447Nachamkin I. 2001. Campylobacter Enteritis and the Guillain-Barre Syndrome. CurrInfect Dis Rep 3, 116-122.Plomp J.J. et al. 1999, Miller Fisher anti-GQ1b antibodies: a-latrotoxin-like effects onmotor endplates. Ann. Neurol. 45, 189-199Rees J.H., Soudain S.E., Gregson N.A. and Hughes R. A.C., 1995., Campylobacter jejuniinfection and Guillain-Barre syndrome, The New England Journal of Medicine, vol.333, no. 21, 1374-1379Rose N.R. and Mackay, I.R. 2000. Molecular mimicry: a critical look at exemplaryinstances in human diseases. Cell. Mol. Life Sci. 57, 542-551Sheikh K. A., I. Nachamkin, T. W. Ho, H. J. Willison, J. Veitch, H. Ung, M. Nicholson, C.Y. Li, H. S. Wu, B. O. Shen, D. R. Cornblath, A. K. Asbury, G. M. McKhann, and J. W.Griffin. 1998. Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome:molecular mimicry and host susceptibility. Neurology 51:371-378.Van Doorn P.A 2008. Clinical features, pathogenesis, and treatment of Guillain-Barresyndrome, The Lancet Neurology, vol. 7, no. 10, 939-950Wirguin I., Briani C., Suturkova-Milosevic L., Fisher T., Della-Latta P., Chalif P., andLatov N., 1997. Induction of anti-GM1 ganglioside antibodies by Campylobacter jejunilipopolysaccharides. J. Neuroimmunol. 78:138-142.Yuki N., Yamada M., M. Koga, 2001. Animal model of axonal Guillain-Barre syndromeinduced by sensitization with GM1 ganglioside, Annals of Neurology, vol. 49, no. 6,pp. 712-720Yuki N., K. Susuki, M. Koga, Y. Nishimoto, M. Odaka, K. Hirata, K. Taguchi, T. Miyatake,K. Furukawa, T. Kobata, and M. Yamada. 2004. Carbohydrate mimicry between humanganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barresyndrome. Proc. Natl. Acad. Sci. USA 101:11404-11409.IndIvIdualIzed epIlepsy treatmentWIth carbamazepIneand valproIc acIdSterjev.Z, Dimovski.iAJ, Suturkova.LjUniversity "St.Cyril and Methodius" Faculty of Pharmacy Skopje,Republic of MacedoniaEpilepsy is a serious chronic neurological disorder, affecting anestimated 42 million people worldwide or 5% from the worldpopulation. About 15 different antiepileptic drugs (AEDs) are currentlyavailable, exhibiting widely varying mechanisms of action. Drug-resistant epilepsy is defined as the persistence of seizures despitetreatment with a range of AEDs, using different mechanisms of actionsingly or in combination at maximum tolerated doses.The mechanismsunderlying the development of drug resistance in epilepsy is a mix ofpharmacokinetic, pharmacodynamic and pharmacogenetic factors.Predictors associated with treatment-resistant epilepsy are differentand include: interindividual differences among patients in theabsorbtion and metabolizing of AED, variability in drug-receptorinteractions, quantity of target receptor etc. The genetic constitutionof individuals exists as a background of individual response to AED andinfluence almost all phases of drug transformation. Carbamazepineand Valproic acid have been subjects of a lot of pharmacogeneticsstudies. Association investigation have been undertaken for genesimplicated in drug transport (MDR1/ABCB1), end-organ drug targets(sodium channel SCN1A) and drug metabolizing enzymes (CYP3A4,CYP3A5, CYP1A2, UGT2B7 and EPHX1).